X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with SHASUN PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SHASUN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SHASUN PHARMA DIVIS LABORATORIES/
SHASUN PHARMA
 
P/E (TTM) x 18.1 123.9 14.6% View Chart
P/BV x 3.9 8.5 46.0% View Chart
Dividend Yield % 1.6 0.2 676.3%  

Financials

 DIVIS LABORATORIES   SHASUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
SHASUN PHARMA
Mar-14
DIVIS LABORATORIES/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,48494 2,636.5%   
Low Rs91846 2,013.4%   
Sales per share (Unadj.) Rs142.3214.2 66.4%  
Earnings per share (Unadj.) Rs41.95.3 784.9%  
Cash flow per share (Unadj.) Rs46.315.8 292.9%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %0.61.4 41.1%  
Book value per share (Unadj.) Rs161.553.3 302.8%  
Shares outstanding (eoy) m265.4756.62 468.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.00.3 3,663.6%   
Avg P/E ratio x40.613.1 310.0%  
P/CF ratio (eoy) x36.74.4 830.8%  
Price / Book Value ratio x10.51.3 803.6%  
Dividend payout %23.918.7 127.4%   
Avg Mkt Cap Rs m451,5253,958 11,408.7%   
No. of employees `0003.7NA-   
Total wages/salary Rs m3,6492,164 168.7%   
Avg. sales/employee Rs Th10,184.4NM-  
Avg. wages/employee Rs Th984.1NM-  
Avg. net profit/employee Rs Th2,998.5NM-  
INCOME DATA
Net Sales Rs m37,76412,127 311.4%  
Other income Rs m848229 369.9%   
Total revenues Rs m38,61212,356 312.5%   
Gross profit Rs m14,1381,009 1,401.1%  
Depreciation Rs m1,182594 199.1%   
Interest Rs m23415 5.6%   
Profit before tax Rs m13,781230 5,999.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,662-73 -3,661.2%   
Profit after tax Rs m11,119302 3,680.2%  
Gross profit margin %37.48.3 449.9%  
Effective tax rate %19.3-31.7 -61.0%   
Net profit margin %29.42.5 1,181.8%  
BALANCE SHEET DATA
Current assets Rs m30,9476,884 449.5%   
Current liabilities Rs m5,1958,456 61.4%   
Net working cap to sales %68.2-13.0 -526.2%  
Current ratio x6.00.8 731.7%  
Inventory Days Days11762 189.4%  
Debtors Days Days85108 79.2%  
Net fixed assets Rs m17,0274,970 342.6%   
Share capital Rs m531113 468.6%   
"Free" reserves Rs m42,3412,875 1,472.8%   
Net worth Rs m42,8773,020 1,419.7%   
Long term debt Rs m51,817 0.3%   
Total assets Rs m49,68413,347 372.3%  
Interest coverage x595.01.6 38,304.3%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.80.9 83.7%   
Return on assets %22.45.4 417.3%  
Return on equity %25.910.0 259.2%  
Return on capital %32.213.3 241.6%  
Exports to sales %85.346.4 183.9%   
Imports to sales %22.914.2 160.9%   
Exports (fob) Rs m32,1985,622 572.8%   
Imports (cif) Rs m8,6541,728 500.9%   
Fx inflow Rs m32,2705,843 552.3%   
Fx outflow Rs m8,7752,173 403.8%   
Net fx Rs m23,4963,669 640.3%   
CASH FLOW
From Operations Rs m10,379398 2,610.5%  
From Investments Rs m-4,135-1,635 252.9%  
From Financial Activity Rs m-6,2411,309 -477.0%  
Net Cashflow Rs m371 4.6%  

Share Holding

Indian Promoters % 52.0 39.2 132.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.6 327.8%  
FIIs % 19.0 17.6 108.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 39.6 43.4%  
Shareholders   31,796 20,750 153.2%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  FRESENIUS KABI ONCO.  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS